These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 34218772)

  • 21. Treatment persistence with aripiprazole once monthly: a 4-year follow-up.
    Fagiolini A; Aguglia E; Ballerini A; Callista G; Carpiniello B; Clerici M; Corrivetti G; Cuomo A; De Fazio P; De Filippis S; De Giorgi S; Goracci A; La Barbera D; Mencacci C; Montagnani G; Pigato G; Vannucchi J; Vita A
    Ann Gen Psychiatry; 2022 Sep; 21(1):39. PubMed ID: 36175924
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multidimensional Assessment of Functional Outcomes in Schizophrenia: Results From QUALIFY, a Head-to-Head Trial of Aripiprazole Once-Monthly and Paliperidone Palmitate.
    Potkin SG; Loze JY; Forray C; Baker RA; Sapin C; Peters-Strickland T; Beillat M; Nylander AG; Hertel P; Nitschky Schmidt S; Eramo A; Hansen K; Naber D
    Int J Neuropsychopharmacol; 2017 Jan; 20(1):40-49. PubMed ID: 27927736
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predictors of persistence in patients with schizophrenia treated with aripiprazole once-monthly long-acting injection in the Spanish clinical practice: a retrospective, observational study.
    Olivares JM; González-Pinto A; Páramo M;
    Eur Psychiatry; 2021 Apr; 64(1):e40. PubMed ID: 33840396
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of aripiprazole lauroxil once-monthly versus aripiprazole once-monthly long-acting injectable formulations in patients with acute symptoms of schizophrenia: an indirect comparison of two double-blind placebo-controlled studies.
    Cameron C; Zummo J; Desai D; Drake C; Hutton B; Kotb A; Weiden PJ
    Curr Med Res Opin; 2018 Apr; 34(4):725-733. PubMed ID: 29179595
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-Term Real-World Effectiveness of Aripiprazole Once-Monthly. Treatment Persistence and Its Correlates in the Italian and Spanish Clinical Practice: A Pooled Analysis.
    Olivares JM; Fagiolini A
    Front Psychiatry; 2022; 13():877867. PubMed ID: 35573364
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Patient-Centered Outcomes with Aripiprazole Once-Monthly for Maintenance Treatment in Patients with Schizophrenia: Results From Two Multicenter, Randomized, Double-Blind Studies.
    Kane JM; Sanchez R; Baker RA; Eramo A; Peters-Strickland T; Perry PP; Johnson BR; Tsai LF; Carson WH; McQuade RD; Fleischhacker WW
    Clin Schizophr Relat Psychoses; 2015; 9(2):79-87. PubMed ID: 25711509
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Aripiprazole once-monthly in the acute treatment of schizophrenia: findings from a 12-week, randomized, double-blind, placebo-controlled study.
    Kane JM; Peters-Strickland T; Baker RA; Hertel P; Eramo A; Jin N; Perry PP; Gara M; McQuade RD; Carson WH; Sanchez R
    J Clin Psychiatry; 2014 Nov; 75(11):1254-60. PubMed ID: 25188501
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effectiveness and Tolerability of Switching to Aripiprazole Once Monthly from Antipsychotic Polypharmacy and/or Other Long Acting Injectable Antipsychotics for Patients with Schizophrenia in Routine Practice: A Retrospective, Observation Study.
    Pae CU; Han C; Bahk WM; Lee SJ; Patkar AA; Masand PS
    Clin Psychopharmacol Neurosci; 2020 Feb; 18(1):153-158. PubMed ID: 31958916
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hospitalisation rates in patients switched from oral anti-psychotics to aripiprazole once-monthly for the management of schizophrenia.
    Kane JM; Sanchez R; Zhao J; Duca AR; Johnson BR; McQuade RD; Eramo A; Baker RA; Peters-Strickland T
    J Med Econ; 2013 Jul; 16(7):917-25. PubMed ID: 23663091
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of aripiprazole lauroxil in patients with acute schizophrenia as assessed by the Positive and Negative Syndrome Scale-supportive analyses from a Phase 3 study.
    Citrome L; Risinger R; Cutler AJ; Du Y; Zummo J; Nasrallah HA; Silverman BL
    CNS Spectr; 2018 Aug; 23(4):284-290. PubMed ID: 28625204
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Paliperidone Palmitate Every Three Months (PP3M) 2-Year Treatment Compliance, Effectiveness and Satisfaction Compared with Paliperidone Palmitate-Monthly (PP1M) in People with Severe Schizophrenia.
    Fernández-Miranda JJ; Díaz-Fernández S; De Berardis D; López-Muñoz F
    J Clin Med; 2021 Apr; 10(7):. PubMed ID: 33915786
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder.
    Swainston Harrison T; Perry CM
    Drugs; 2004; 64(15):1715-36. PubMed ID: 15257633
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effectiveness of Antipsychotic Drugs for 24-Month Maintenance Treatment in First-Episode Schizophrenia: Evidence From a Community-Based "Real-World" Study.
    Zhang C; Chen MJ; Wu GJ; Wang ZW; Rao SZ; Zhang Y; Yi ZH; Yang WM; Gao KM; Song LS
    J Clin Psychiatry; 2016 Nov; 77(11):e1460-e1466. PubMed ID: 28076667
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clozapine combined with different antipsychotic drugs for treatment-resistant schizophrenia.
    Barber S; Olotu U; Corsi M; Cipriani A
    Cochrane Database Syst Rev; 2017 Mar; 3(3):CD006324. PubMed ID: 28333365
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetics, Safety, and Tolerability of a 2-Month Dose Interval Regimen of the Long-Acting Injectable Antipsychotic Aripiprazole Lauroxil: Results From a 44-Week Phase I Study.
    Weiden PJ; Du Y; von Moltke L; Wehr A; Hard M; Marandi M; Walling DP
    CNS Drugs; 2020 Sep; 34(9):961-972. PubMed ID: 32621071
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-effectiveness Analysis of Aripiprazole Once-Monthly for the Treatment of Schizophrenia in the UK.
    Tempest M; Sapin C; Beillat M; Robinson P; Treur M
    J Ment Health Policy Econ; 2015 Dec; 18(4):185-200. PubMed ID: 26729007
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term efficacy and safety of aripiprazole in patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder: 26-week prospective study.
    Kwon JS; Jang JH; Kang DH; Yoo SY; Kim YK; Cho SJ;
    Psychiatry Clin Neurosci; 2009 Feb; 63(1):73-81. PubMed ID: 19154213
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetics, tolerability and safety of aripiprazole once-monthly in adult schizophrenia: an open-label, parallel-arm, multiple-dose study.
    Mallikaarjun S; Kane JM; Bricmont P; McQuade R; Carson W; Sanchez R; Forbes RA; Fleischhacker WW
    Schizophr Res; 2013 Oct; 150(1):281-8. PubMed ID: 23890595
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A prospective, multicentre, open-label study to evaluate the effectiveness of aripiprazole in the treatment of a broad range of patients with schizophrenia.
    Peuskens J; Bervoets C; Kok F; Delatte B; Touquet G; Gillain B; de Patoul A; Halkin V; Loze JY; Vansteelandt K; Constant E
    Eur Psychiatry; 2012 Oct; 27(7):506-12. PubMed ID: 21920707
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Atypical antipsychotics for psychosis in adolescents.
    Kumar A; Datta SS; Wright SD; Furtado VA; Russell PS
    Cochrane Database Syst Rev; 2013 Oct; 2013(10):CD009582. PubMed ID: 24129841
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.